Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up

By Josh Enomoto, InvestorPlace Contributor

While speculative investments are terribly risky, gamblers who know what they’re doing may be interested in these penny sleeper stocks.

7 Under-$50 Sleeper Stocks to Buy Before Wall Street Wakes Up

By Josh Enomoto, InvestorPlace Contributor

For those with a budget that may be restricted right now, perhaps it's time to check out these under-$50 sleeper stocks to buy right now.

Why Is BioAffinity (BIAF) Stock Up 40% Today?

By Josh Enomoto, InvestorPlace Contributor

BioAffinity received roughly $7.7 million in warrant exercises, bringing a cash infusion to the otherwise challenged BIAF stock.

7 Small-Cap Sleeper Stocks to Buy Before Wall Street Wakes Up

By Josh Enomoto, InvestorPlace Contributor

While these market ideas may be flying under the radar, certain small-cap sleeper stocks to buy pack quite the punch.

Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results

By Josh Enomoto, InvestorPlace Contributor

Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring.

Load More